Rani Therapeutics Holdings Inc Asset Resilience Ratio
Rani Therapeutics Holdings Inc asset resilience ratio. Rani Therapeutics Holdings Inc (RANI) has an Asset Resilience Ratio of 79.75% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Rani Therapeutics Holdings Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Rani Therapeutics Holdings Inc (2021–2025)
Asset resilience ratio of Rani Therapeutics Holdings Inc from 2021 to 2025. This chart shows how Rani Therapeutics Holdings Inc's Asset Resilience Ratio has changed over time. Read Rani Therapeutics Holdings Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Rani Therapeutics Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Rani Therapeutics Holdings Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $48.52 Million | 79.75% |
| Total Liquid Assets | $48.52 Million | 79.75% |
Asset Resilience Insights
- Very High Liquidity: Rani Therapeutics Holdings Inc maintains exceptional liquid asset reserves at 79.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rani Therapeutics Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Rani Therapeutics Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Rani Therapeutics Holdings Inc Asset Resilience Ratio by Year (2021–2025)
Rani Therapeutics Holdings Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Rani Therapeutics Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.04% | $31.09 Million | $58.62 Million | -12.14pp |
| 2024-12-31 | 65.18% | $23.88 Million | $36.63 Million | -8.51pp |
| 2023-12-31 | 73.68% | $42.67 Million | $57.92 Million | +7.52pp |
| 2022-12-31 | 66.16% | $71.47 Million | $108.03 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $124.21 Million | -- |
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug subst… Read more